The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-03-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: multiplesubjectsprclinical relevanceevidence of
  Phrases that lowered it: healthy malejudgedthe rangepharmacokineticsmale subjects
• Drug's FAERS reports marked serious: 55.0% (lowers risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past termination rate: 5.3% (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 133 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: 55 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 49022 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 301 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin) NCT02254148 · started 2014 · scored riskier than 4% of active trials completed
• A Study in Healthy Men and Women to Test Whether BI 1358894 Influences the Amount of Bupropion in the Blood NCT04899674 · started 2021 · scored riskier than 6% of active trials completed
• A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood NCT05738291 · started 2023 · scored riskier than 14% of active trials completed
• A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood NCT06367153 · started 2024 · scored riskier than 3% of active trials completed
• Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide NCT01536366 · started 2009 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.